2-hydroxynonadecanoic acid | 93361-63-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-hydroxynonadecanoic acid
• 英文别名: 1-Hydroxy-octadecan-carbonsaeure-(1)；2-Hydroxy-nonadecansaeure；hydroxynonadecanoic acid
• CAS: 93361-63-8
• 化学式: C₁₉H₃₈O₃
• 分子量: 314.509
• InChiKey: PYNCEZHRMYECCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  22
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 2-hydroxynonadecanoic acid
  参考文献：
  名称：

  Oskerko, Zhurnal Russkago Fiziko-Khimicheskago Obshchestva, 1914, vol. 46, p. 414,416

  摘要：

  DOI：

文献信息

• Lipids That Increase Insulin Sensitivity And Methods Of Using The Same
  申请人：BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

  公开号：US20160221925A1

  公开（公告）日：2016-08-04

  The invention provides, inter alia, fatty acyl hydroxy fatty acid (FAHFA; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders—including diabetes-related disorders, Metabolic Syndrome, polycystic ovarian syndrome, cancer, and inflammatory disorders—using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate FAHFA levels, FAHFA-mediated signaling, and FAHFA-mediated biological effects.

  该发明提供了脂肪酰羟基脂肪酸（FAHFA；一类新型的酯脂类分子）以及用于诊断和治疗各种疾病的方法，包括与糖尿病相关的疾病、代谢综合征、多囊卵巢综合征、癌症和炎症性疾病等；以及筛选可用于治疗这些疾病和/或调节FAHFA水平、FAHFA介导信号传导和FAHFA介导生物效应的其他化合物的方法。
• [EN] LIPIDS THAT INCREASE INSULIN SENSITIVITY AND METHODS OF USING THE SAME<br/>[FR] LIPIDES AUGMENTANT LA SENSIBILITÉ À L'INSULINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BETH ISREAL DEACONESS MEDICAL CT INC

  公开号：WO2013166431A1

  公开（公告）日：2013-11-07

  The invention provides, inter alia, fatty acyl hydroxy fatty acid (FAHFA; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders- including diabetes-related disorders, Metabolic Syndrome, polycyctic ovarian syndrome, cancer, and inflammatory disorders— using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate FAHFA levels, FAHFA-mediated signaling, and FAHFA-mediated biological effects.

  这项发明提供了脂肪酰羟基脂肪酸（FAHFA；一类新型的酯脂类分子）以及用于治疗各种疾病的诊断和治疗方法，包括与糖尿病相关的疾病、代谢综合征、多囊卵巢综合征、癌症和炎症性疾病，以及使用它们的方法；以及筛选对这些疾病有用或调节FAHFA水平、FAHFA介导的信号传导和FAHFA介导的生物效应的其他化合物的方法。
• 20-HETE antagonists and agonists
  申请人：——

  公开号：US20020049244A1

  公开（公告）日：2002-04-25

  20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z), 8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.

  20-HETE激动剂和拮抗剂以及其治疗应用已被披露。在本发明的一种优选形式中，20-HETE激动剂被选自包括21-羟基油酸-5(Z), 8(Z),11(Z),14(Z)-四烯酸，20-羟基二十碳-5(Z),14(Z)-二烯酸和20-,21-二甲基20-HETE的组中。优选的20-HETE拮抗剂包括5(S)-HETE，15(S)-HETE，19(S)-HETE，19-羟基十九酸-5(Z),8(Z),11(Z),14(Z)-四烯酸和20-羟基二十碳-6(Z),15(Z)-二烯酸。
• COMPOSITIONS COMPRISING POLYMERS PREPARED FROM 2-HYDROXYALKYL ACIDS
  申请人：Moeller Michael

  公开号：US20130131190A1

  公开（公告）日：2013-05-23

  Described herein are compositions comprising polymers prepared by melt polycondensation of 2-hydroxyalkyl acids. Methods of making and using the compositions are also disclosed.

  本文描述了由2-羟基烷基酸熔融缩聚制备的聚合物组成物。还公开了制备和使用该组成物的方法。
• 20- Hete antagonists and agonists
  申请人：——

  公开号：US20020072534A1

  公开（公告）日：2002-06-13

  20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),4(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),ll(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.

  本发明揭示了20-HETE激动剂和拮抗剂及其治疗应用。在本发明的一种优选形式中，20-HETE激动剂选自以下组合：21-羟基十九碳五烯酸5(Z),8(Z),11(Z),14(Z)-四烯酸，20-羟基二十碳五烯酸5(Z),4(Z)-二烯酸和20-,21-二甲基20-HETE。优选的20-HETE拮抗剂包括5(S)-HETE，15(S)-HETE，19(S)-HETE，19-羟基十九碳五烯酸8(Z),11(Z),14(Z)-四烯酸和20-羟基二十碳6(Z),15(Z)-二烯酸。